Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
GAITHERSBURG, Md., May 25, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA. These data will demonstrate the company’s ability to predict phenotypic resistance across antibiotic classes for Gram-negative infections using rapid genetic testing and predictive algorithms from its Acuitas Lighthouse® Knowledgebase. It will also showcase advances in being able to discriminate bacterial strains using more genes to solve current limitations with conventional strain typing methods.
The details for the poster presentations at ASM Microbe are as follows:
Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance
Poster title: Predicting Antibiotic Resistance in Gram-Negative Bacilli by Rapid Detection of Resistance Genes (#87)
Presenter: Terry Walker, Ph.D.
Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT
Location: Exhibit Hall D, Exhibit and Poster Hall
Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance
Poster title: Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of Escherichia coli (#72)
Presenter: Weizhong Chang, Ph.D.
Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT
Location: Exhibit Hall D, Exhibit and Poster Hall
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen®, Acuitas®, Acuitas Lighthouse® and QuickFISH® are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: Cammy Duong MacDougall Biomedical Communications 781-591-3443 [email protected]
